Table 4.

Association of key CD4 count and HIV RNA level predictors for overall NHL risk by NHL subtypes, NA-ACCORD, 1996–2014.

Key predictors for overall NHL risk	Non-Hodgkin lymphoma (NHL) subtypes
	Central nervous system NHL (CNS-NHL)		Diffuse large B-cell lymphoma (DLBCL)		Burkitt lymphoma (BL)		Other specified NHL		NHL not otherwise specified (NHL-NOS)

	Cases	HR (95% CI)^a	Cases	HR (95% CI)^a	Cases	HR (95% CI)^a	Cases	HR (95% CI)^a	Cases	HR (95% CI)^a
	Recent CD4 count (i.e., 180 d lag), cells per μL^b
<50	25	96·6 (10·2–917·6)	23	2·4 (1·4–4·3)	2	0·5 (0·1–2·6)	1	0·3 (0·04–2·7)	9	3·5 (1·2–9·6)
50–<100	1	5·2 (0·3–96·2)	25	2·9 (1·7–5·0)	1	0·3 (0·04–2·5)	6	2·4 (0·8–6·6)	8	3·7 (1·4–10·1)
100–<200	1	2·2 (0·1–39·6)	34	1·7 (1·1–2·7)	6	0·8 (0·3–2·3)	11	1·8 (0·8–4·1)	7	1·4 (0·5–3·8)
200–<350	1	1·3 (0·1–22·2)	42	1·2 (0·8–1·8)	11	1·0 (0·4–2·3)	8	0·7 (0·3–1·7)	16	1·9 (0·9–4·2)
350–<500	4	6·0 (0·6–54·0)	37	1·1 (0·7–1·7)	5	0·5 (0·2–1·5)	15	1·4 (0·7–2·8)	9	1·2 (0·5–2·9)
≥500	1	1·0 (ref)	52	1·0 (ref)	12	1·0 (ref)	19	1·0 (ref)	11	1·0 (ref)
Global p-value		<0·0001		0·0011		0·61		0·098		0·082
Per 50 cells per μL		0·65 (0·54–0·79)		0·95 (0·92–0·98)		1·04 (0·97–1·11)		0·97 (0·91–1·02)		0·95 (0·89–1·01)
P-trend		<0·0001		0·0035		0·29		0·25		0·088
Late HIV RNA level average, copies per mL^c,d
≤500	2	1·0 (ref)	46	1·0 (ref)	3	1·0 (ref)	22	1·0 (ref)	8	1·0 (ref)
>500–<10,000	2	1·3 (0·2–9·7)	43	1·9 (1·2–2·9)	9	8·3 (2·2–31·6)	11	1·1 (0·5–2·3)	16	3·2 (1·3–7·6)
10,000–<100,000	11	3·2 (0·6–18·9)	84	3·9 (2·6–5·9)	19	23·8 (6·7–85·2)	18	2·2 (1·1–4·5)	21	4·4 (1·8–10·8)
≥100,000	18	9·7 (1·5–61·1)	40	7·7 (4·6–13·0)	6	48·1 (10·7–216·6)	9	5·9 (2·3–14·8)	15	11·7 (4·3–32·3)
Global p-value		0·0059		<0·0001		<0·0001		0·0026		<0·0001
Per log10 copies per mL		3·64 (1·95–6·79)		1·95 (1·68–2·26)		3·33 (2·28–4·86)		1·51 (1·16–1·97)		2·12 (1·58–2·83)
P-trend		<0·0001		<0·0001		<0·0001		0·0020		<0·0001

NHL=non-Hodgkin lymphoma.

From competing risks, event-and-cohort-stratified, Cox model adjusted for sex, race/ethnicity, and baseline age and calendar period among persons with follow-up >1260 days. N= 68,585 times 5 (augmented dataset for analyzing five events [i.e., NHL subtypes]); number of NHL cases= 403 (33, 213, 37, 60, and 60 cases for CNS-NHL, DLBCL, BL, other specified NHL, and NHL-NOS, respectively).

Global p-heterogeneity for measure modeled as categorical and continuous was <0·0001 and <0·0001, respectively. P-heterogeneity for measure modeled as categorical and continuous for pairwise comparisons as follows: CNS-NHL vs. DLBCL (<0·0001 and <0·0001, for categorical and continuous, respectively), CNS-NHL vs. BL (<0·0001 and <0·0001), CNS-NHL vs. other specified NHL (<0·0001 and <0·0001), and CNS-NHL vs. NHL-NOS (<0·0001 and <0·0001), DLBCL vs. BL (0·091 and 0·032), DLBCL vs. other specified NHL (0·18 and 0·65), DLBCL vs. NHL-NOS (0·80 and 0·85), BL vs. other specified NHL (0·12 and 0·13), BL vs. NHL-NOS (0·14 and 0·053), and other specified NHL vs. NHL-NOS (0·060 and 0·61).

Global p-heterogeneity for measure modeled as categorical and continuous was 0·16 and 0·0028, respectively. P-heterogeneity for measure modeled as categorical and continuous for pairwise comparisons as follows: CNS-NHL vs. DLBCL (0·78 and 0·042, for categorical and continuous, respectively), CNS-NHL vs. BL (0·36 and 0·81), CNS-NHL vs. other specified NHL (0·97 and 0·0066), and CNS-NHL vs. NHL-NOS (0·83 and 0·11), DLBCL vs. BL (0·025 and 0·0074), DLBCL vs. other specified NHL (0·48 and 0·098), DLBCL vs. NHL-NOS (0·62 and 0·62), BL vs. other specified NHL (0·0039 and 0·0005), BL vs. NHL-NOS (0·15 and 0·060), and other specified NHL vs. NHL-NOS (0·31 and 0·091).

HIV RNA average during the late moving window (i.e., from 1260 to 180 days in the past).